A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Phase 1
40
about 1.1 years
18+
3 sites in FL, NY, OH
What this study is about
This trial is testing a treatment combination of JNJ-86974680 and Pasritamig to see if it's safe and effective for people with advanced prostate cancer. The goal is to find the best dose of this combination that can be used in future studies.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take JNJ-86974680
- 2.Take Pasritamig
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Adverse Events (AEs) by Severity, Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Secondary: Duration of Response (DOR), Objective Response Rate (ORR), Prostate-Specific Antigen (PSA) Response Rate, Radiographic Progression-Free Survival (rPFS), Time to Response (TTR)
Oncology